Sartorius Stedim Biotech S.A./ADR
No enriched coverage for $SDMHF in the last 7 days.
No SEC Form 4 filings for $SDMHF in the last 30 days.
See all $SDMHF insider activity →Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.
UBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.
Sartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.
Recent SDMHF coverage spans financial news, market movers and earnings.
Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.
UBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.
Sartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.
UBS upgraded Sartorius Stedim Biotech to buy, raising its price target to €260 from €220. JP Morgan upgraded Michelin to overweight, increasing its target to €42 from €35. JP Morgan also trimmed Elis's target to €28.20, while UBS raised Getlink's to €19.80.
Sartorius Stedim Biotech reported 1H 2026 sales revenue of EUR 1,527m, up 6.4% in constant currencies including U.S. tariff refunds and customer surcharge compensation. Underlying EBITDA was EUR 479m (31.4% margin) and net profit EUR 181m. Management confirmed 2026 guidance for sales growth of 6% to 10% in constant currencies and EBITDA margin slightly above 31%.
AlphAI scores every news story that mentions SDMHF with an AI model for sentiment and relevance, and aggregates insider trades from Sartorius Stedim Biotech S.A./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.
1 min readUBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.
1 min readSartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.
2 min readUBS upgraded Sartorius Stedim Biotech to buy, raising its price target to €260 from €220. JP Morgan upgraded Michelin to overweight, increasing its target to €42 from €35. JP Morgan also trimmed Elis's target to €28.20, while UBS raised Getlink's to €19.80.
1 min readSartorius Stedim Biotech reported 1H 2026 sales revenue of EUR 1,527m, up 6.4% in constant currencies including U.S. tariff refunds and customer surcharge compensation. Underlying EBITDA was EUR 479m (31.4% margin) and net profit EUR 181m. Management confirmed 2026 guidance for sales growth of 6% to 10% in constant currencies and EBITDA margin slightly above 31%.
4 min read